Please select the option that best describes you:
Do you think about CDK4/6 inhibitor selection differently in a patient with de novo rather than recurrent metastatic disease?
Subgroup analyses in MONALEESA-2 suggest more benefit in de novo treatment naive patients, which is in contrast to MONARCH-3 data presented at ESMO 2022 where hazard ratio was similar in these patient groups.
Answer from: Medical Oncologist at Academic Institution
Not really. Would recommend endocrine therapy with CDK 4/6i for both patients with de novo metastatic disease and those with disease recurrence. The type of endocrine therapy might vary though - would consider Fulvestrant as endocrine therapy partner for a patient who has disease recurrence on adjuv...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
No. The selection of first line CDK4/6 inhibitors is dependent on different things including overall survival data, patient characteristics, and other factors elaborated in the answer to the next question. Exploratory subgroup analysis of MONALEESA-2 showed OS benefit in various subgroups consistent...